Startups
Proteomedix enables personalized medicine by developing non-invasive diagnostic tests to detect and assess the prognosis of cancer, as well as to match patients with safer and more effective therapies.
The first product is a blood-based test for the early diagnosis of prostate cancer. The main benefit of this test is a significantly higher accuracy compared to today’s clinical standard (blood-based PSA test). This reduces unnecessary biopsies and thus results in significant cost savings for the healthcare system and less discomfort for the patient.
The first product is a blood-based test for the early diagnosis of prostate cancer. The main benefit of this test is a significantly higher accuracy compared to today’s clinical standard (blood-based PSA test). This reduces unnecessary biopsies and thus results in significant cost savings for the healthcare system and less discomfort for the patient.
Overview
Location
United States, Indiana, York
Employees
11-50
Total raised
$18.12M
Founded date
2010
Investors 2
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| VentureLab | venturelab.swiss |
Funding Rounds 5
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Aug 19, 2016 | Funding round | $5.21M | |
| Jan 27, 2015 | Series B round | $1.11M | |
| Apr 9, 2014 | Series B round | $3.63M | |
| Jan 27, 2012 | Series A round | $2.84M |
Mentions in press and media 29
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Dec 18, 2023 | Proteomedix acquired by US company | |
| Jun 9, 2023 | Proteomedix set for growth | |
| Apr 28, 2023 | Proclarix on the way to a worldwide standard | |
| Sep 24, 2021 | Chinese cancer screening company invests in Proteomedix | Proteomedix is a healthcare company whose mission is to transform prostate cancer diagnosis. The company has identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis and therapy management. The lead product... |
| May 27, 2020 | Industry experts take the lead in startups' management | InterAx Biotech With PICARD, InterAx built an innovative and unique lead discovery platform for the design and selection of drug candidates. For its growth phase, the startup has made changes in the top management by appointing Kurt Kessler... |
| May 27, 2020 | Industry experts take the lead in startups' management | |
| Apr 2, 2020 | Erstes Labor setzt auf Prostata-Test von Proteomedix | |
| Apr 2, 2020 | Erstes Labor setzt auf Prostata-Test von Proteomedix | Der Markteintritt ist für Proteomedix gelungen. Das Zentrum für Labormedizin St. Gallen bietet den Test nun an. "Proclarix ist eine wichtige neue Entscheidungshilfe für Ärzte zur Verbesserung der Prostatakrebs-Diagnostik bei Männern mi... |
| Feb 26, 2020 | Proteomedix announces commercial launch of its blood-based test for prostate cancer | Proteomedix announced today the market entry of Proclarix. The test combines proprietary biomarkers and a risk score with a proprietary algorithm that accurately identifies an individual patient’s risk for clinically significant prostate ca... |
Show more
Reviews 0
FAQ about Proteomedix AG
When was Proteomedix AG founded?
Proteomedix AG was founded in 2010.
How much funding has Proteomedix AG raised?
Proteomedix AG has raised $18.12M in total across 5 funding rounds.
What funding rounds has Proteomedix AG raised?
Parsers VC lists 5 funding rounds of Proteomedix AG, among them a funding round of $5.21M on Aug 19, 2016, a Series B round of $1.11M on Jan 27, 2015 and a Series B round of $3.63M on Apr 9, 2014.
Who has invested in Proteomedix AG?
Parsers VC lists 2 investors of Proteomedix AG, among them VentureLab.
What has the press written about Proteomedix AG?
Parsers VC has collected 29 articles mentioning Proteomedix AG, among them “Proteomedix acquired by US company” (Dec 18, 2023) and “Proteomedix set for growth” (Jun 9, 2023).
Is Proteomedix AG still active?
Yes, Proteomedix AG is active; its latest activity on Parsers VC dates from Oct 15, 2026.